Intraperitoneal injection of thalidomide alleviates early osteoarthritis development by suppressing vascular endothelial growth factor expression in mice

Song,Jia  Lin; Li,De  Long; Fang,Hang; Cai,Dao  Zhang

doi:10.3892/mmr.2018.8980

Intraperitoneal injection of thalidomide alleviates early osteoarthritis development by suppressing vascular endothelial growth factor expression in mice

Authors:
- Jia Lin Song
- De Long Li
- Hang Fang
- Dao Zhang Cai
View Affiliations

Affiliations: Department of Orthopedics, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510630, P.R. China
Published online on: May 7, 2018 https://doi.org/10.3892/mmr.2018.8980
Pages: 571-579

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vascular endothelial growth factor (VEGF) is expressed in articular cartilage and increases in expression levels have been associated with the progression of osteoarthritis (OA). Thalidomide is a drug that has been reported to inhibit angiogenesis and reduce VEGF production by downregulating VEGF expression. The objective of the present study was to determine whether intraperitoneal administration of thalidomide may attenuate early OA development in mice. Male C57BL/6 mice (10‑weeks‑old) were randomly assigned into the destabilization of the medial meniscus (Dmm) with thalidomide treatment (Dmm+Th), Dmm and Sham groups equally. An OA model was induced surgically in Dmm+Th and Dmm groups, and mice of the Dmm+Th group were subsequently treated with an intraperitoneal injection of thalidomide (200 mg/kg/day). At 2 and 4 weeks following surgery, the pathological alterations in cartilage samples were assessed qualitatively by hematoxylin and eosin staining and Safranin O/Fast green staining, and quantitatively by the Osteoarthritis Research Society International scoring system. The mRNA expression levels of matrix metalloproteinase‑13 (MMP‑13) and VEGF were measured by reverse transcription‑quantitative polymerase chain reaction. The protein expression levels of MMP‑13 and VEGF were detected by immunofluorescence and immunohistochemistry, respectively. The production of VEGF in serum was evaluated via an ELISA assay. Pathological scores were significantly higher in the Dmm and the Dmm+Th groups than those in the Sham group; however, the Dmm+Th group exhibited markedly less severe pathological changes compared with the Dmm group. Compared with the Sham group, the mRNA and protein expression levels of VEGF and MMP‑13 in the Dmm and the Dmm+Th groups were significantly increased. The Dmm+Th group exhibited significantly decreased expression levels of VEGF and MMP‑13, as well as significantly decreased serum VEGF concentration compared with the Dmm group. Thus, the results of the present study demonstrated that intraperitoneal administration of thalidomide may alleviate the development of early OA by suppressing VEGF expression in mice and may have potential as a novel therapy for the treatment of OA.

View Figures

View References

1	Bitton R: The economic burden of osteoarthritis. Am J Manag Care. 15 Suppl 8:S230–S235. 2009.PubMed/NCBI
2	Ackerman IN, Pratt C, Gorelik A and Liew D: Projected burden of osteoarthritis and rheumatoid arthritis in Australia: A population-level analysis. Arthritis Care Res (Hoboken). 2017.
3	Cicuttini FM and Wluka AE: Osteoarthritis: Is OA a mechanical or systemic disease? Nat Rev Rheumatol. 10:515–516. 2014. View Article : Google Scholar : PubMed/NCBI
4	Musumeci G, Szychlinska MA and Mobasheri A: Age-related degeneration of articular cartilage in the pathogenesis of osteoarthritis: Molecular markers of senescent chondrocytes. Histol Histopathol. 30:1–12. 2015. View Article : Google Scholar : PubMed/NCBI
5	Srikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D and Jones G: A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis Cartilage. 13:769–781. 2005. View Article : Google Scholar : PubMed/NCBI
6	Felson DT: An update on the pathogenesis and epidemiology of osteoarthritis. Radiol Clin North Am. 42:1–9. 2004. View Article : Google Scholar : PubMed/NCBI
7	Wei Y and Bai L: Recent advances in the understanding of molecular mechanisms of cartilage degeneration, synovitis and subchondral bone changes in osteoarthritis. Connect Tissue Res. 57:245–261. 2016. View Article : Google Scholar : PubMed/NCBI
8	van der Kraan PM and van den Berg WB: Chondrocyte hypertrophy and osteoarthritis: Role in initiation and progression of cartilage degeneration? Osteoarthritis Cartilage. 20:223–232. 2012. View Article : Google Scholar : PubMed/NCBI
9	Fosang AJ, Last K, Knauper V, Murphy G and Neame PJ: Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Lett. 380:17–20. 1996. View Article : Google Scholar : PubMed/NCBI
10	Pufe T, Petersen W, Tillmann B and Mentlein R: The splice variants VEGF121 and VEGF189 of the angiogenic peptide vascular endothelial growth factor are expressed in osteoarthritic cartilage. Arthritis Rheum. 44:1082–1088. 2001. View Article : Google Scholar : PubMed/NCBI
11	Enomoto H, Inoki I, Komiya K, Shiomi T, Ikeda E, Obata K, Matsumoto H, Toyama Y and Okada Y: Vascular endothelial growth factor isoforms and their receptors are expressed in human osteoarthritic cartilage. Am J Pathol. 162:171–181. 2003. View Article : Google Scholar : PubMed/NCBI
12	Pfander D, Körtje D, Zimmermann R, Weseloh G, Kirsch T, Gesslein M, Cramer T and Swoboda B: Vascular endothelial growth factor in articular cartilage of healthy and osteoarthritic human knee joints. Ann Rheum Dis. 60:1070–1073. 2001. View Article : Google Scholar : PubMed/NCBI
13	Pufe T, Harde V, Petersen W, Goldring MB, Tillmann B and Mentlein R: Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in immortalized chondrocytes. J Pathol. 202:367–374. 2004. View Article : Google Scholar : PubMed/NCBI
14	Shen P, Jiao Z, Zheng JS, Xu WF, Zhang SY, Qin A and Yang C: Injecting vascular endothelial growth factor into the temporomandibular joint induces osteoarthritis in mice. Sci Rep. 5:162442015. View Article : Google Scholar : PubMed/NCBI
15	Tibesku CO, Daniilidis K, Skwara A, Paletta J, Szuwart T and Fuchs-Winkelmann S: Expression of vascular endothelial growth factor on chondrocytes increases with osteoarthritis-an animal experimental investigation. Open Orthop J. 5:177–180. 2011. View Article : Google Scholar : PubMed/NCBI
16	Yuan Q, Sun L, Li JJ and An CH: Elevated VEGF levels contribute to the pathogenesis of osteoarthritis. BMC Musculoskelet Disord. 15:4372014. View Article : Google Scholar : PubMed/NCBI
17	Nagai T, Sato M, Kutsuna T, Kokubo M, Ebihara G, Ohta N and Mochida J: Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repair. Arthritis Res Ther. 12:R1782010. View Article : Google Scholar : PubMed/NCBI
18	Therapontos C, Erskine L, Gardner ER, Figg WD and Vargesson N: Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci USA. 106:8573–8578. 2009. View Article : Google Scholar : PubMed/NCBI
19	D'Amato RJ, Loughnan MS, Flynn E and Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 91:4082–4085. 1994. View Article : Google Scholar : PubMed/NCBI
20	Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 341:1565–1571. 1999. View Article : Google Scholar : PubMed/NCBI
21	Tan H, Chen H, Xu C, Ge Z, Gao Y, Fang J, Liu W and Xiao S: Role of vascular endothelial growth factor in angiodysplasia: An interventional study with thalidomide. J Gastroenterol Hepatol. 27:1094–1101. 2012. View Article : Google Scholar : PubMed/NCBI
22	Mercurio A, Adriani G, Catalano A, Carocci A, Rao L, Lentini G, Cavalluzzi MM, Franchini C, Vacca A and Corbo F: A mini-review on thalidomide: Chemistry, mechanisms of action, therapeutic potential and anti-angiogenic properties in multiple myeloma. Curr Med Chem. 24:2736–2744. 2017. View Article : Google Scholar : PubMed/NCBI
23	Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N and Vangsted AJ: Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. Int J Cancer. 131:E636–E642. 2012. View Article : Google Scholar : PubMed/NCBI
24	Behl T, Kaur I, Goel H and Kotwani A: Significance of the antiangiogenic mechanisms of thalidomide in the therapy of diabetic retinopathy. Vascul Pharmacol. 92:6–15. 2017. View Article : Google Scholar : PubMed/NCBI
25	Israyelyan A, Shannon EJ, Baghian A, Kearney MT and Kousoulas KG: Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn. Cancer Chemother Pharmacol. 64:1201–1210. 2009. View Article : Google Scholar : PubMed/NCBI
26	Lainer-Carr D and Brahn E: Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol. 3:434–442. 2007. View Article : Google Scholar : PubMed/NCBI
27	Gordon JN and Goggin PM: Thalidomide and its derivatives: Emerging from the wilderness. Postgrad Med J. 79:127–132. 2003. View Article : Google Scholar : PubMed/NCBI
28	Vasheghani F, Zhang Y, Li YH, Blati M, Fahmi H, Lussier B, Roughley P, Lagares D, Endisha H, Saffar B, et al: PPARγ deficiency results in severe, accelerated osteoarthritis associated with aberrant mTOR signalling in the articular cartilage. Ann Rheum Dis. 74:569–578. 2015. View Article : Google Scholar : PubMed/NCBI
29	Kotoh T, Dhar DK, Masunaga R, Tabara H, Tachibana M, Kubota H, Kohno H and Nagasue N: Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery. 125:536–544. 1999. View Article : Google Scholar : PubMed/NCBI
30	Liu CY, Jiang XX, Zhu YH and Wei DN: Metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine produces antidepressant effects in rats: Role of brain-derived neurotrophic factor. Neuroscience. 223:219–224. 2012. View Article : Google Scholar : PubMed/NCBI
31	Glasson SS, Chambers MG, Van Den Berg WB and Little CB: The OARSI histopathology initiative-recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthritis Cartilage. 18 Suppl 3:S17–S23. 2010. View Article : Google Scholar : PubMed/NCBI
32	Huang MJ, Wang L, Jin DD, Zhang ZM, Chen TY, Jia CH, Wang Y, Zhen XC, Huang B, Yan B, et al: Enhancement of the synthesis of n-3 PUFAs in fat-1 transgenic mice inhibits mTORC1 signalling and delays surgically induced osteoarthritis in comparison with wild-type mice. Ann Rheum Dis. 73:1719–1727. 2014. View Article : Google Scholar : PubMed/NCBI
33	Jonason JH, Hoak D and O'Keefe RJ: Primary murine growth plate and articular chondrocyte isolation and cell culture. Methods Mol Biol. 1226:11–18. 2015. View Article : Google Scholar : PubMed/NCBI
34	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
35	Vargesson N: Thalidomide-induced teratogenesis: History and mechanisms. Birth Defects Res C Embryo Today. 105:140–156. 2015. View Article : Google Scholar : PubMed/NCBI
36	Alberto SF, Felix J and de Deus J: Thalidomide for the treatment of severe intestinal bleeding. Endoscopy. 40:788–789. 2008. View Article : Google Scholar : PubMed/NCBI
37	Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
38	Gu X, Zheng Y, Ren B, Zhang R, Mei F, Zhang J and Ma Z: Intraperitoneal injection of thalidomide attenuates bone cancer pain and decreases spinal tumor necrosis factor-alpha expression in a mouse model. Mol Pain. 6:642010. View Article : Google Scholar : PubMed/NCBI
39	Daruwalla J, Nikfarjam M, Malcontenti-Wilson C, Muralidharan V and Christophi C: Effect of thalidomide on colorectal cancer liver metastases in CBA mice. J Surg Oncol. 91:134–140. 2005. View Article : Google Scholar : PubMed/NCBI
40	Kenyon BM, Browne F and D'Amato RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 64:971–978. 1997. View Article : Google Scholar : PubMed/NCBI
41	Xia B, Di Chen, Zhang J, Hu S, Jin H and Tong P: Osteoarthritis pathogenesis: A review of molecular mechanisms. Calcif Tissue Int. 95:495–505. 2014. View Article : Google Scholar : PubMed/NCBI
42	Brinckerhoff CE and Matrisian LM: Matrix metalloproteinases: A tail of a frog that became a prince. Nat Rev Mol Cell Biol. 3:207–214. 2002. View Article : Google Scholar : PubMed/NCBI
43	Klein T and Bischoff R: Physiology and pathophysiology of matrix metalloproteases. Amino Acids. 41:271–290. 2011. View Article : Google Scholar : PubMed/NCBI
44	Tetlow LC, Adlam DJ and Woolley DE: Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: Associations with degenerative changes. Arthritis Rheum. 44:585–594. 2001. View Article : Google Scholar : PubMed/NCBI
45	Baragi VM, Becher G, Bendele AM, Biesinger R, Bluhm H, Boer J, Deng H, Dodd R, Essers M, Feuerstein T, et al: A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum. 60:2008–2018. 2009. View Article : Google Scholar : PubMed/NCBI
46	Hu Y, Xiang JS, DiGrandi MJ, Du X, Ipek M, Laakso LM, Li J, Li W, Rush TS, Schmid J, et al: Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg Med Chem. 13:6629–6644. 2005. View Article : Google Scholar : PubMed/NCBI
47	Janusz MJ, Bendele AM, Brown KK, Taiwo YO, Hsieh L and Heitmeyer SA: Induction of osteoarthritis in the rat by surgical tear of the meniscus: Inhibition of joint damage by a matrix metalloproteinase inhibitor. Osteoarthritis Cartilage. 10:785–791. 2002. View Article : Google Scholar : PubMed/NCBI
48	Janusz MJ, Hookfin EB, Heitmeyer SA, Woessner JF, Freemont AJ, Hoyland JA, Brown KK, Hsieh LC, Almstead NG, De B, et al: Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthritis Cartilage. 9:751–760. 2001. View Article : Google Scholar : PubMed/NCBI
49	Ferrara N and Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 161:851–858. 1989. View Article : Google Scholar : PubMed/NCBI
50	Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362:841–844. 1993. View Article : Google Scholar : PubMed/NCBI
51	Thysen S, Luyten FP and Lories RJ: Targets, models and challenges in osteoarthritis research. Dis Model Mech. 8:17–30. 2015. View Article : Google Scholar : PubMed/NCBI
52	Glyn-Jones S, Palmer AJ, Agricola R, Price AJ, Vincent TL, Weinans H and Carr AJ: Osteoarthritis. Lancet. 386:376–387. 2015. View Article : Google Scholar : PubMed/NCBI